Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…

Fresenius Medical Care AG
Next earnings Aug 4, 2026 · consensus $1.04 EPS, $4.80B rev
Strong net margin (22.3%).
Quality fundamentals and an attractive price line up (~38% below fair value) — the rarer case where both the business and the entry look good.
Sources: SEC EDGAR (CIK 0001333141, latest 6-K filed 2026-05-28) · EODHD · as of 6/21/2026, 2:31:48 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
Fresenius Medical Care AG shows $4.97B in FY2013 revenue, a 22.3% net margin, and 10.3% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY09 | FY10 | FY11 | FY12 | FY13 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | $4.97B |
| Gross profit | $3.83B | $3.84B | $4.15B | $4.60B | $4.74B |
| Operating income | $1.76B | $1.92B | $2.07B | $2.22B | $2.26B |
| Net income | $891M | $979M | $1.07B | $1.19B | $1.11B |
| Diluted EPS | $2.99 | $3.24 | $3.51 | $3.87 | $3.65 |
| Net margin | — | — | — | — | 22.3% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Source: EODHD. Yield = trailing-12-month dividends ÷ price.
1482 tracked peers · median
Disclosed under the STOCK Act
Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.